Cycle length 8 to 12 weeks on, 4 to 6 weeks off in common research community protocols
Disclosure of interest: Anastasios Mavridis: Nothing to Disclose, Adam Viktorisson: Nothing to Disclose, Bjrn Eliasson: Nothing to Disclose, Mia von Euler: Nothing to Disclose, Katharina S Sunnerhagen: Nothing to Disclose Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.04 - STROKE COMPLICATIONS P999 - ESOC25-160 PREDICTORS OF 90-DAY OUTCOMES AND HEMORRHAGIC RISK AFTER ENDOVASCULAR THROMBECTOMY WITH STENT RELEASE IN PATIENTS WITH ACUTE CAROTID ARTERY ATHEROSCLEROTIC ISCHEMIC STROKE Gaia Mignani 1 , Marta Del Chicca 1 , Nicola Giannini 1 , Marco Baldini 1 , Roberto D'agliano 1 , Alessandro Grigolini 2 , Giacomo Petrucci 2 , Filippo Baldacci 1 , Mirco Cosottini 2 1 Neurological Clinic, University of Pisa, Pisa, Italy, 2 Neuroradiology Unit, University of Pisa, Pisa, Italy Background and Aims: To investigate clinical and procedural factors associated with the 90-day modified Rankin Scale (mRS) and symptomatic intracranial hemorrhage (sICH) at 6 and 12 hours after endovascular thrombectomy (EVT) with carotid stent release
A plateau on a stable dose is an expected endpoint rather than proof that semaglutide has stopped working
Pain typically localizes to the front of the hip and groin area
Daily activities requiring grip may elicit symptoms, and patients frequently complain of hand numbness and tingling when reading a book, using a screwdriver, and while driving
It is not approved as a medicine, supplement or therapeutic product in the UK or any other jurisdiction
